Issuer's Statement
-
The Company and the entire Board of Directors guarantee that the content of this Prospectus is true, accurate, and complete, with no false or misleading statements or material omissions. They undertake to fulfill their commitments in good faith and bear corresponding legal responsibilities.
-
This Prospectus has been prepared in accordance with the "Administrative Measures for the Registration of Securities Offerings by Publicly Listed Companies," "Format and Content Disclosure Rules for Publicly Issued Securities of Listed Companies No. 61 — Prospectus and Offering Status Report for Publicly Issued Securities by Listed Companies to Specific Objects," and other relevant requirements.
-
Upon completion of this private placement to specific objects through a simplified procedure, the Company will be solely responsible for changes in its operations and earnings. Investors will bear their own investment risks arising from this private placement.
-
This Prospectus is a statement by the Company's Board of Directors regarding this private placement to specific objects through a simplified procedure. Any statement inconsistent with this Prospectus is a false statement.
-
Investors with any questions should consult their stockbroker, lawyer, certified public accountant, or other professional advisor.
-
The matters described in this Prospectus do not represent the substantive judgment, confirmation, or approval of the offering by the approval authorities. The effectiveness and completion of this private placement to specific objects through a simplified procedure are subject to approval or registration by the relevant authorities.
Major Event Notice
This Major Event Notice serves only to remind investors of risk factors and other important matters requiring their special attention. Investors are urged to read the entire section "Risk Factors Related to This Offering" in the Prospectus.
I. This private placement to specific objects through a simplified procedure has been authorized by the Company's 2025 Annual General Meeting of Shareholders for implementation by the Board of Directors. It has been approved by the 19th meeting of the 6th Board of Directors and the 2nd meeting of the 7th Board of Directors. It is subject to review and approval by the Shenzhen Stock Exchange and registration and approval by the China Securities Regulatory Commission (CSRC) before it can be implemented.
II. The specific objects for this offering are Yuecai (Zhongshan) Biomedical Investment Partnership (Limited Partnership), Nord Fund Management Co., Ltd., Caitong Fund Management Co., Ltd., and Yang Yin, totaling four specific objects. This complies with the CSRC and other securities regulatory authorities' regulations limiting the number of offering objects to no more than thirty-five. All offering objects will subscribe for the Company's shares in this offering with cash.
III. Based on investor subscription quotations and strictly following the procedures and rules for determining the offering price, offering objects, and allocated share quantities in the subscription invitation letter, the offering price has been set at RMB 10.22 per share.
The pricing benchmark date for this offering is the first day of the offering period (August 4, 2026). The offering price is not less than 80% of the Company's average stock price for the 20 trading days prior to the pricing benchmark date (Average stock price for the 20 trading days prior to the pricing benchmark date = Total trading volume of the Company's stock in the 20 trading days prior to the pricing benchmark date / Total trading volume of the Company's stock in the 20 trading days prior to the pricing benchmark date).
If the Company distributes cash dividends, bonus shares, or capital reserve transfers during the period from the pricing benchmark date to the issuance date, the offering price will be adjusted accordingly in accordance with the relevant regulations of the Shenzhen Stock Exchange.